Skip to main content
MLTX
NASDAQ Life Sciences

MoonLake 10-Q: $498.5M Cash to Mid-2028, Q3 Net Loss $79.5M, 85.1M Shares Out

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.62
Mkt Cap
$995.748M
52W Low
$9.46
52W High
$23.29
52W Position info
23% above low
Off High info
50% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MLTX sits 23% above its 52-week low of $9.46.

Summary

MoonLake's Q3 10-Q shows $498.5 million in cash and securities with runway to mid-2028, a $79.5 million quarterly net loss swollen by a $17.0 million accrued Merck milestone, and 85.1 million shares outstanding after this year's equity raises.


Key Events · Earnings and Guidance · MLTX

  • Q3 Net Loss $79.5M on Milestone Accrual

    Net loss was $79.5 million, or $0.93 per share, versus $70.7 million a year ago. R&D of $68.9 million included a $17.0 million accrued regulatory milestone to Merck KGaA tied to expected BLA acceptance.

  • Cash $498.5M, Runway to Mid-2028

    Cash, equivalents and short-term marketable debt securities totaled $498.5 million at September 30, down from $537 million at June 30, with management guiding to funding into mid-2028.

  • Share Count Up to 85.1M

    Shares outstanding rose to 85,106,685 from 71,373,579 at December 31, 2025, reflecting the June 2026 offering, the 1,500,000-share over-allotment exercise and ATM sales.

  • ATM: $50.3M Sold, $300M Left

    Under the Leerink sales agreement, 2,764,178 shares were sold in the nine months at a weighted average of $18.52 for $50.3 million net; the full $300.0 million prospectus supplement remained available at quarter-end.


Analysis · MLTX · Life Sciences

Hard numbers now sit behind this morning's Q3 release. Cash and short-term securities of $498.5 million, down from $537 million at June 30, fund operations into mid-2028, so there is no near-term financing need. The quarter's $79.5 million net loss, however, was inflated by a $17.0 million accrued milestone to Merck KGaA tied to the expected FDA acceptance of the sonelokimab BLA — a one-time step-up rather than a new run-rate. Share count stands at 85,106,685 versus 71,373,579 at year-end, the cumulative cost of the June offering, its over-allotment and $50.3 million of ATM sales at an $18.52 average. Next hard date: the FDA's acceptance decision on the BLA, expected by end-November 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLTX was trading at $11.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $995.7M. The 52-week trading range was $9.46 to $23.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.82 info
Change: +$0.2153 (+2%) info
Market Cap: $957.45M info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $11.82 info
Change: +$0.2053 (+2%) info
Market Cap: $957.45M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.82 info
Change: +$0.0046 (+0.04%) info
Market Cap: $957.45M info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $11.82 info
Change: -$5.29 (-31%) info
Market Cap: $957.45M info
MLTX
Aug 10, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $11.82 info
Change: -$4.37 (-27%) info
Market Cap: $957.45M info